Lung Cancer |

Venous Thromboembolism and EGFR Mutation Status in Advanced Adenocarcinoma of Lung FREE TO VIEW

Natalie Berger, MD; D. Datta, MD; Susan Tannenbaum, MD
Author and Funding Information

University of Connecticut Health Center, Farmington, CT

Chest. 2014;146(4_MeetingAbstracts):600A. doi:10.1378/chest.1977798
Text Size: A A A
Published online


SESSION TITLE: Lung Cancer Posters II

SESSION TYPE: Original Investigation Poster

PRESENTED ON: Wednesday, October 29, 2014 at 01:30 PM - 02:30 PM

PURPOSE: Venous thromboembolism (VTE) is a major cause of death in patients with cancer. Modern targeted therapies such as antiangiogenic agents targeting endothelial growth factor receptor (EGFR) are associated with an increased risk of VTE. A recent meta-analysis revealed that anti-EGFR agents used in the treatment of solid malignancies increases the risk of VTE by 32%. What factors predispose to the development of VTE in these patients is not known and has not been explored. The incidence of VTE in EGFR- negative lung cancer patients, in comparison to EGFR positive patients being treated with anti-EGFR agents is not known. The objective of this study was to compare the incidence of VTE in patients with advanced lung adenocarcinoma with EGFR- negative status versus patients who were EGFR-positive.

METHODS: Medical Records of patients with stage IIIB and stage IV lung adenocarcinoma, being treated at our institution over the last 3 years, was reviewed. The following data was obtained from records: patient demographics, EGFR status, and the number of patients who developed VTE. Linear regression was performed to determine the correlation between EGFR status and development of VTE. p < 0.05 was deemed statistically significant.

RESULTS: Of 57 patients with stage IIIB and stage IV lung adenocarcinoma, mean age was 70 ± 13 years; 44% of patients were males. Only 23 patients (42%) had their EGFR status tested. Of these, 7 were EGFR-positive and 16 were EGFR- negative. Three out of seven (42%) of the EGFR-positive patients developed VTE and 2 out of 16 (12%) of the EGFR-negative patients developed VTE. On student's t- test, this was not statistically significant ( p=0.5).

CONCLUSIONS: The occurrence of VTE was not significantly higher in the EGFR-positive patients, compared to EGFR negative patients. These results are different from previous studies but the small number of study subjects, may have affected results.

CLINICAL IMPLICATIONS: Further studies, in a larger group of patients, should be performed to determine what factors, besides treatment with anti-EGFR agents, predispose to the development of VTE in EGFR-positive patients with adenocarcinoma of lung.

DISCLOSURE: The following authors have nothing to disclose: Natalie Berger, D. Datta, Susan Tannenbaum

No Product/Research Disclosure Information




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543